期刊文献+

Solid lipid microparticles:An approach for improving oral bioavailability of aspirin

下载PDF
导出
摘要 The objectives of the work were to develop a lipid based delivery system for aspirin and to evaluate its physicochemical and pharmacodynamic properties.Aspirin-loaded solid lipid microparticles(SLMs)were formulated by hot homogenization and analysed for their encapsulation efficiency(EE%),in vitro release,particle size,anti-inflammatory and ulcer inhibition properties.Particle size ranged from 33.10±5.85 to 43.50±7.27μm for batches A1 to A3 SLMs loaded with 1,3 and 5%aspirin and containing Poloxamer 407,while batches B1,B2 and B3 formulated with Soluplus as surfactant had particle size range of 31.10±1.46 to 45.60±2.92μm.Batches A1 and B1 containing 1%of aspirin had the highest EE of 70 and 72%respectively.Maximum in vitro release of 95.1 and 93.2%were obtained at 8 h from batches A1 and B1 respectively.SLMs exhibited about 77.8%oedema inhibition,while the reference had 66.7%and ulcer inhibition range of 25-75%.Aspirin-loaded SLMs exhibited good properties and could be used orally twice daily for the treatment of inflammation.
出处 《Asian Journal of Pharmaceutical Sciences》 SCIE CAS 2015年第5期425-432,共8页 亚洲药物制剂科学(英文)
  • 相关文献

参考文献1

二级参考文献27

  • 1Hansen, C.M., "The three dimensional solubility parameter-key to paint component affinities. 1: solvent,plasticizers, polymers and resins", J. Paint Technol., 39,104-117(1967).
  • 2Kreveken, D.V., Properties of Polymers, Elsevier, Amsterdam (1990).
  • 3Li, J.S., Sun, J., Zhang, D.L., "Estimating the solubility parameters of rubber ingredients basing on group contribution", Rubber Eng., 42(7), 393-395(1995). (in Chinese)
  • 4Jenning, V., Gohla, S., "Comparison of wax and glyceride solid lipid nanoparficles", Int. J. Pharm., 196,219-222(2000).
  • 5Sato, K., "Crystallization behaviour of fats and lipids-A review", Chem. Eng. Sci., 56, 2255-2265(2001).
  • 6Hagemann, J.W., Crystallization and Polymorphism of Fats and Fatty Acids, Marcel Dekker Inc., New York (1988).
  • 7Freitas, C., Miiller, R.H., "Correlation between long-term stability of solid lipid nanoparticles (SLN) and crystallinity of the lipid phase", Eur. J. Pharm. Biopharm., 47, 125-132(1999).
  • 8Mühlen, A.Z., Schwarz, C., Mehnert, W., "Solid lipid nanoparticles (SLN) for controlled drug delivery-Drug release and release mechanism", Eur. J. Pharm. Biopharm., 45, 149-155(1998).
  • 9Chapman, D., "The polymorphism of glycerides", Chem.Rev, 62, 433-456(1962).
  • 10Mehnert, W., Mader, K., "Solid lipid nanoparticles production, characterization and applications", Adv. Drug Deliv. Rev., 47, 165-196(2001).

共引文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部